These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35902386)

  • 41. Different insulin types and regimens for pregnant women with pre-existing diabetes.
    O'Neill SM; Kenny LC; Khashan AS; West HM; Smyth RM; Kearney PM
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD011880. PubMed ID: 28156005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metformin monotherapy for adults with type 2 diabetes mellitus.
    Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus.
    Pollock RF; Norrbacka K; Boye KS; Osumili B; Valentine WJ
    J Med Econ; 2022; 25(1):393-402. PubMed ID: 35105267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.
    Erpeldinger S; Rehman MB; Berkhout C; Pigache C; Zerbib Y; Regnault F; Guérin E; Supper I; Cornu C; Kassaï B; Gueyffier F; Boussageon R
    BMC Endocr Disord; 2016 Jul; 16(1):39. PubMed ID: 27391319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
    Visser J; Snel M; Van Vliet HA
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003990. PubMed ID: 17054193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus.
    Colunga-Lozano LE; Gonzalez Torres FJ; Delgado-Figueroa N; Gonzalez-Padilla DA; Hernandez AV; Roman Y; Cuello-García CA
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011296. PubMed ID: 30488948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for gestational diabetes mellitus based on different risk profiles and settings for improving maternal and infant health.
    Tieu J; McPhee AJ; Crowther CA; Middleton P; Shepherd E
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007222. PubMed ID: 28771289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.
    Yki-Järvinen H
    Drugs; 2000 Nov; 60(5):975-83. PubMed ID: 11129129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
    Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
    Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.
    Simmons RK; Borch-Johnsen K; Lauritzen T; Rutten GE; Sandbæk A; van den Donk M; Black JA; Tao L; Wilson EC; Davies MJ; Khunti K; Sharp SJ; Wareham NJ; Griffin SJ
    Health Technol Assess; 2016 Aug; 20(64):1-86. PubMed ID: 27583404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
    Udell JA; Cavender MA; Bhatt DL; Chatterjee S; Farkouh ME; Scirica BM
    Lancet Diabetes Endocrinol; 2015 May; 3(5):356-66. PubMed ID: 25791290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
    Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J;
    Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study.
    Madsen LR; Baggesen LM; Richelsen B; Thomsen RW
    Diabetologia; 2019 Apr; 62(4):611-620. PubMed ID: 30734055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
    Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pioglitazone for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Clar C; Ebrahim SH
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006060. PubMed ID: 17054272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.